1. Advances in understanding the molecular pathology of gynecological malignancies: the role and potential of RNA sequencing
- Author
-
Mona El-Bahrawy and Alba Southern
- Subjects
EXPRESSION ,Genital Neoplasms, Female ,neoplasms ,Computational biology ,Genome ,OVARIAN-CANCER ,Fusion gene ,Transcriptome ,03 medical and health sciences ,0302 clinical medicine ,TUMOR ,Gene expression ,Medicine ,BREAST-CANCER ,Humans ,1112 Oncology and Carcinogenesis ,Oncology & Carcinogenesis ,Gene ,030304 developmental biology ,0303 health sciences ,Science & Technology ,business.industry ,Molecular pathology ,Sequence Analysis, RNA ,Alternative splicing ,gynecology ,Obstetrics and Gynecology ,RNA ,Obstetrics & Gynecology ,SEQ DATA ,High-Throughput Nucleotide Sequencing ,GENE ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Life Sciences & Biomedicine - Abstract
For many years technological limitations restricted the progress of identifying the underlying genetic causes of gynecologicalcancers. However, during the past decade, high-throughput next-generation sequencing technologies have revolutionized cancer research. RNA sequencing has arisen as a very useful technique in expanding our understanding of genome changes in cancer. Cancer is characterized by the accumulation of genetic alterations affecting genes, including substitutions, insertions, deletions, translocations, gene fusions, and alternative splicing. If these aberrant genes become transcribed, aberrations can be detected by RNA sequencing, which will also provide information on the transcript abundance revealing the expression levels of the aberrant genes. RNA sequencing is considered the technique of choice when studying gene expression and identifying new RNA species. This is due to the quantitative and qualitative improvement that it has brought to transcriptome analysis, offering a resolution that allows research into different layers of transcriptome complexity. It has also been successful in identifying biomarkers, fusion genes, tumor suppressors, and uncovering new targets responsible for drug resistance in gynecological cancers. To illustrate that we here review the role of RNA sequencing in studies that enhanced our understanding of the molecular pathology of gynecological cancers.
- Published
- 2021